^
Association details:
| Biomarker: | NOTCH1 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)
Published date:
01/11/2018
Excerpt:
...we evaluated the efficacy of ibrutinib as single agent, in a real-life contest...Significant shorter PFS and OS were observed in NOTCH1 M patients (39% vs 71% and 71% vs 81% at 24 months, respectively; p=0.03 and p=0.02; Figures B and C).
DOI:
10.1182/blood-2018-99-113074
